ZK 200775 hydrate

• Catalog No.: Z4777
• M. F.: C14H17F3N3O7P
• M. W.: 427.2696506
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: {[7-(morpholin-4-yl)-2,3-dioxo-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoxalin-1-yl]methyl}phosphonic acid hydrate
• IUPAC Traditional name: [7-(morpholin-4-yl)-2,3-dioxo-6-(trifluoromethyl)-4H-quinoxalin-1-yl]methylphosphonic acid hydrate
• Synonyms: MPQX; Fanapanel; [[3,4-Dihydro-7-(4-morpholinyl)-2,3-dioxo-6-(trifluoromethyl)-1(2H)-quinoxalinyl]methyl]-phosphonic acid hydrate

DATABASE IDS

• MDL Number: MFCD18452859

PROPERTIES

• Empirical Formula (Hill Notation): C14H15F3N3O6P · xH2O
• Purity: ≥98% (HPLC)
• Apperance: off-white to light brown powder
• Solubility: DMSO: ≥20 mg/mL
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

General description
ZK 200775 is a selective AMPA/kainite receptor antagonist with very low affinity for NMDA associated binding sites (Ki for CNQX binding site = 32 nM vs. 2.8 uM for DCKA binding site.) ZK 200775 displays superior PK and safety profiles in in vivo studies compared to quinoxalinedione antagonists such as NBQX, showing no effects on motor behavior or cardiac events at efficacious doses in rat. Additionally, unlike other quinoxalinediones, ZK 200775 is water soluble, making this a desirable tool compound for in vivo studies.

Description (简体中文)

General description
ZK 200775 is a selective AMPA/kainite receptor antagonist with very low affinity for NMDA associated binding sites (Ki for CNQX binding site = 32 nM vs. 2.8 uM for DCKA binding site.) ZK 200775 displays superior PK and safety profiles in in vivo studies compared to quinoxalinedione antagonists such as NBQX, showing no effects on motor behavior or cardiac events at efficacious doses in rat. Additionally, unlike other quinoxalinediones, ZK 200775 is water soluble, making this a desirable tool compound for in vivo studies.